Data from EMC - Curated by Toby Galbraith - Last updated 12 September 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Obesity

Learn about the complex factors influencing development of obesity.

Visit Obesity

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

Visit Hyperammonaemia

Related Content

More information

Category Value
Agency product number EMEA/H/C/000854
Orphan designation No
Date First Approved 23-07-2007
Type Medicinal product not subject to medical prescription
Marketing authorisation holder Glaxo Group Ltd.